A Registry Study of Biomarkers in Ischemic Heart Disease ( BIOMS-IHD )
- Conditions
- Cardiovascular Diseases
- Registration Number
- NCT05965882
- Lead Sponsor
- Beijing Institute of Heart, Lung and Blood Vessel Diseases
- Brief Summary
The registry study aims to discover biomarkers for accurate classification and risk assessment of ischemic heart disease.
- Detailed Description
The purpose of this study is to discover biomarkers for early identification, diagnosis, molecular classification, and intervention based on the mechanism of ischemic heart disease（IHD）. Using mass spectrometry-based metabolomics and multimodal imaging technology, the study aims to further construct a new system for early risk stratification of IHD based on abnormal metabolites.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 5000
Not provided
- Current known inability to follow instructions or comply with follow-up procedures.
- Eligible patients without informed consent form
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of hospitalizations for acute heart failure (HF) These data is collected during follow-up visit at 3/6/12/24/36/48 months after discharge Unplanned emergency visits or hospitalizations leading to HF deterioration were defined as hospitalizations for HF
- Secondary Outcome Measures
Name Time Method Number of major adverse cardiovascular events (MACE) These data is collected during follow-up visit at 3/6/12/24/36/48 months after discharge Major adverse cardiovascular events (MACE) in overall population, defined as composite of all-cause death, Heart Failure hospitalization, recurrent myocardial infarction, stroke or ischemia-driven revascularization.
Trial Locations
- Locations (1)
Beijing Anzhen Hospital
🇨🇳Beijing, Beijing, China